This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Hydrochlorothiazide (HCTZ)

Cheap, generic, evidence-rich first-line thiazide diuretic for hypertension.

Aliases (7)

HCTZ · HCT · Microzide · Esidrix · HydroDIURIL · Oretic · thiazide

TYPICAL DOSE

12.5-25 mg PO once daily; rarely 50 mg

Daily

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Hydrochlorothiazide (HCTZ)?

Hydrochlorothiazide (HCTZ) is a thiazide diuretic prescription medication. It is widely used to treat hypertension, edema, and certain calcium-handling disorders.

Key Benefits

Reduces blood pressure, treats fluid retention from heart failure or kidney disease, lowers urinary calcium excretion (useful in calcium-stone disease), and is one of the most cost-effective first-line antihypertensives.

Mechanism of Action

Inhibits the Na+/Cl- cotransporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing urinary water loss. The resulting volume reduction and modest vasodilation lower systemic blood pressure.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Peptide Interactions

Medical:

Synergistic

ACEi/ARB combos (lisinopril/HCTZ, valsartan/HCTZ, telmisartan/HCTZ) — synergistic BP lowering with K+ neutralization

Medical:

Synergistic

Loop diuretic in resistant edema (sequential nephron blockade)

Lithium

Avoid

(HCTZ ↑ lithium reabsorption → toxicity)

Other K+-wasting drugs

Avoid

(loop diuretics, corticosteroids, amphotericin) without supplementation

Bodybuilding:

Avoid

Other diuretics (furosemide stacked with thiazide for "synergy") — has killed competitors

Beta-2 agonists

Avoid

(clenbuterol stack — additive K+ loss)

NSAIDs chronically

Avoid

(blunts BP effect, raises kidney injury risk)

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety

Common (>10%): Hypokalemia (especially at 50 mg+), hyponatremia (especially elderly), hypomagnesemia, hyperuricemia, mild hyperglycemia, mild dyslipidemia, photosensitivity
Less common (1-10%): Sexual dysfunction, gout flare, dizziness, dehydration
Rare-serious (<1%):
- Severe hypokalemia → fatal arrhythmia. This is the bodybuilding-cutting kill mechanism — torsades de pointes, V-fib on stage or in dressing room.
- Hyponatremic encephalopathy (especially with low-Na intake)
- Acute angle-closure glaucoma (idiosyncratic — small risk window first weeks)
- Pancreatitis (rare)
- Stevens-Johnson syndrome / TEN (very rare)
- Skin cancer (non-melanoma) — Danish registry data 2017-2018 showed ~7× increased risk of squamous cell carcinoma with cumulative high HCTZ exposure due to photosensitization. FDA / EMA added label warnings.
Specific watch periods: First 2 weeks for hyponatremia/hypokalemia; ongoing photoprotection; periodic SCC skin checks for chronic users